Vor Biopharma, a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer, announced the formation of a collaboration with Janssen Biotech, Inc.
7992332 nan items 1 apa default asc 1
Incorporation of functional PZP domain of AF10 into the leukemogenic CALM-AF10 fusion prevented the transforming activity of the fusion in bone marrow-derived hematopoietic stem and progenitor cells in vitro and in vivo and abrogated CALM-AF10-mediated leukemogenesis in vivo.
7992332 ZPTZKLVC items 1 apa default asc 1
Researchers uncovered and experimentally validated that a CD44+ subpopulation of placental endothelial cells exhibited hemogenic potential.
6445218 V62M8E79 items 1 apa default asc 1
Scientists review the relevance and complications of clonal hematopoiesis for the treatment of hematologic malignancies with cell therapeutic approaches.
6445212 7AUB4CVJ items 1 apa default asc 1
Luspatercept is a promising alternative to ESAs for a subset of transfusion-dependent patients with lower risk myelodysplastic syndromes, namely those with a sideroblastic phenotype who are either not suitable for or have already failed erythropoietin-based treatment.
[Expert Review of Hematology]
7992332 7Y6HUW29 items 1 apa default asc 1
Scientists found that resident macrophage deficiency prevents storage of lipids in adipocytes from wild-type and Ccr2–/– mice fed a high-fat diet, as well as hyperphagic leptin receptor–deficient mice.
6445218 MJUHZ3V5 items 1 apa default asc 1
Researchers demonstrated that genotoxic vectors induced a unique gene expression signature linked to stemness and oncogenesis in transduced murine hematopoietic stem- and progenitor cells, and developed the Surrogate Assay for Genotoxicity Assessment.
7992332 VNPBL6V5 items 1 apa default asc 1
Scientists investigated the spatial organization and transcriptional profile of individual HSCs in both wild type and Tet2−/− fetal livers, by multiplexed error robust fluorescence in situ hybridization.
7992332 4T5S9RMR items 1 apa default asc 1
Investigators discuss recent therapeutic advances and innovative treatment strategies in chronic myelomonocytic leukemia (CMML), including global and molecularly targeted approaches, and discuss what may help to make progress in the design of rationally derived and disease-modifying therapies for CMML.
7992332 Z5DCGQ49 items 1 apa default asc 1
With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of acute lymphoblastic leukemia in both younger and older adults has substantially improved.
Researchers investigated the effects of reducing the dose of posttransplantation cyclophosphamide (PTCy) followed by α-galactosylceramide, a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect.
6445212 BWTF6XYK items 1 apa default asc 1
Nakamura, M., Meguri, Y., Ikegawa, S., Kondo, T., Sumii, Y., Fukumi, T., Iwamoto, M., Sando, Y., Sugiura, H., Asada, N., Ennishi, D., Tomida, S., Fukuda-Kawaguchi, E., Ishii, Y., Maeda, Y., & Matsuoka, K. (2021). Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Scientific Reports, 11(1), 13125. https://doi.org/10.1038/s41598-021-92526-z Cite